Islet Cells Transported Using Sanguine's PHER-O2 Are Transplanted Into Humans
Tuesday November 30, 6:30 am ET
PASADENA, Calif.--(BUSINESS WIRE)--Nov. 30, 2004--Sanguine Corporation (OTCBB:SGNC - News), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced its product, PHER-O2 was used to transport pancreas islet cells. The islet cells were transplanted into two humans at the University of Alberta in Edmonton, Canada. The University's two human islet cell transplants were an unqualified success. These trials, conducted by the University, are for the use of PHER-O2 in the transportation and transplantation of pancreas islet cells. A second group of 20 samples of PHER-O2 has recently been delivered to the University.
Thomas Drees, Ph.D., chairman and CEO of Sanguine Corporation, stated, "As I previously noted, Diabetes is the fastest growing chronic disease in the U.S. and the world. Islet cells produce insulin, which diabetics lack. The work underway at the University of Alberta relates to the transportation of islet cells. The pancreas islet cells are harvested from donors. The cells are then transported for use in human diabetics, whose islet cells are not producing insulin properly. The work completed by the Alberta University with the first two humans whereby islet cells were transported using PHER-O2 is working quite well. Transplantation without oxygen supplementation as provided by PHER-O2 has been troublesome."
Dr. Drees further noted, "In March of 2003, data showing that transplanting healthy, insulin producing islet cells by infusion into the portal vein to the liver enables uncontrolled type 1 diabetic patients to become insulin free, was presented at the 28th Annual Scientific Meeting of the Society of Interventional Radiology. The early data presented shows that if one can get enough healthy islet cells to the liver, diabetes patients could potentially be cured, according to Richard Owen, M.D., interventional radiologist at an Alberta Hospital. The islet cells become rapidly engrafted into the liver and secrete insulin almost immediately. The study showed that the interventional radiology delivery technique provides reliable and safe access to the liver, and together with islet cell separation techniques and immunosuppressive treatment offers a significant development in the treatment of type 1 diabetes. With the success of transporting islet cells using PHER-O2, we see the potential for using PHER-O2 in numerous other organ transplant transportation, which was successfully done with Fluosol DA. The first generation oxygen carrier, for kidneys, livers and heart/lung transplants."
Sanguine Corporation is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including: transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors and hemorrhagic shock. The Company is also developing non-medical applications for its perfluorocarbon (PFC) product.
More information on the Society of Interventional Radiology can be found at www.SIRweb.org.
For information related to the Sanguine Corporation, contact: Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
